| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IRIDEX Corporation$1.12
0 (0%)
Market Cap
17.58 M
EPS
-0.19
P/E Ratio
-
Value Trade
106.45 K
SEC Financials
Q2 2026Dilution Risk
Revenue
11.80 M
R&D Expenses
905.00 K
Operating CF
-1.33 M
Total Assets
28.27 M
Total Liabilities
23.54 M
Equity
4.73 M
D/E Ratio
12,345
-0.98 %
Week
-4.72 %
1 Month
-28.4 %
3 Month
9.78 %
6 Month
-86.88 %
5 Year
-90.15 %
All Time
Cash Data
Cash Position
4.59 M
Monthly Burn
445.00 K
Runway
8.8 mo
Burn Trend
SEC Filing
May 19, 2026
Overview
Volume
29.57 K
52 Week Range
0.87 - 1.65
% held by Insiders
30.16 %
% held by Institutions
16.61 %
Enterprise Value
23.26 M
Total Shares
17.40 M
Short %
0.18 %
Float Shares
11.85 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IRIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IRIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IRIXIridex to Present at the Planet MicroCap Las Vegas 2026 Conference
Iridex Corporation will present at the Planet MicroCap Las Vegas 2026 Conference on June 17. The presentation will be accessible via a live and archived webcast. Iridex specializes in laser-based medical systems for treating glaucoma and retinal diseases, showcasing their innovative MicroPulse technology.
Read more →IRIXIridex Reports First Quarter 2026 Financial Results 2026 Guidance Affirmed
Iridex Corporation reported its financial results for the first quarter ending April 4, 2026, revealing a slight revenue decline to $11.8 million compared to the previous year. Key growth was noted in the Cyclo G6 product family, but the total revenue was impacted by decreased retina system sales due to supply chain and regulatory delays. Operating expenses were reduced by 4%, contributing to a positive outlook for cash flow in the fiscal year. The company has reaffirmed its annual revenue guidance of $51 million to $53 million, factoring in market disruptions in the Middle East that affect product delivery timelines.
Read more →IRIXIridex to Report First Quarter 2026 Financial Results on May 19, 2026
Iridex Corporation has announced its plans to release financial results for the first quarter of 2026 on May 19, 2026. Following the announcement, the management team will host a conference call to discuss the results and provide a business update. Investors can participate via phone or through a live webcast on the company's website.
Read more →IRIXIridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
Iridex Corporation has partnered with EyeProGPO to provide its members with preferred pricing on advanced retina laser technologies. This collaboration aims to enhance access to Iridex's laser products, including the PASCAL® and IQ laser platforms, thereby improving operational efficiency for ophthalmology practices. The partnership underscores Iridex's commitment to supporting healthcare providers with innovative solutions.
Read more →IRIX▼ -26.7%on this news
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Iridex Corporation reported strong financial results for Q4 and full year 2025, with a 16% increase in revenue driven by higher sales in its retina and glaucoma product lines. The company achieved positive adjusted EBITDA for the first time, while also reducing operating expenses. However, gross margins declined due to rising manufacturing costs and the company anticipates challenges in 2026 due to market disruptions in the Middle East.
Read more →IRIXIridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Iridex Corporation has announced it will release its financial results for Q4 and the full year of 2025 on March 26, 2026. The company will also provide a business update during a conference call scheduled for the same day. Investors can participate in the call or access a webcast through the company's website.
Read more →IRIXIridex Announces Plans to Relocate Headquarters
Iridex Corporation has announced plans to relocate its headquarters from Mountain View to San Jose, California. The move is expected to save approximately $0.4 million in fiscal year 2026 and $0.6 million annually thereafter. CEO Patrick Mercer emphasized the importance of reducing operating expenses and maintaining talent acquisition in the Bay Area. However, the lease terms remain non-binding and subject to change.
Read more →IRIX▲ +28.7%on this news
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow
Iridex Corporation announced preliminary unaudited operational and financial results for Q4 and full year 2025. The company expects total revenue between $52.5 million and $52.7 million, representing an increase of up to 8% compared to 2024. In Q4 alone, revenue is projected to rise by 15% to 17%, with positive cash flow reported. Additionally, Iridex highlighted successful sales of its Cyclo G6 products, indicating a strong market demand and operational efficiency. These results remain subject to final auditing and adjustments.
Read more →IRIXIridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Corporation announced the publication of a study demonstrating the safety and effectiveness of retreatment using MicroPulse technology in glaucoma management. Conducted at the University Eye Clinic Maastricht, the study showed significant intraocular pressure reductions in patients after retreatment. The findings support MicroPulse TLT as a valuable option for patients experiencing diminished IOP-lowering benefits over time.
Read more →IRIXIridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex Corporation announced a new study published in Translational Vision Science & Technology that examines the thermal dynamics of transscleral laser treatments for glaucoma. The study, led by Dr. Tomas M. Grippo, compares continuous wave transscleral cyclophotocoagulation and MicroPulse technology. Findings indicate that MicroPulse TLT offers a smaller thermal zone and lower peak temperatures, suggesting a potential for safer treatment. The research aims to enhance clinical practices for both laser techniques in glaucoma management.
Read more →IRIXIridex to Present at the Sidoti Year-End Virtual Investor Conference
Iridex Corporation has announced its participation in the Sidoti Year-End Virtual Investor Conference scheduled for December 11, 2025. During this event, management will present at 10:45 am ET, and interested parties will be able to access both live and archived webcasts via the company’s website. Iridex is noted for its advanced laser-based medical systems, particularly for treating glaucoma and retinal diseases, showcasing its position in the ophthalmology market.
Read more →IRIX▼ -19.8%on this news
Iridex Reports Third Quarter 2025 Financial Results
Iridex Corporation reported its third quarter 2025 financial results, showcasing an 8% year-over-year revenue increase driven by strong sales of glaucoma probes and the Pascal laser system. The company reduced operating expenses and anticipates a positive adjusted EBITDA for the full year. Despite a net loss, the outlook remains optimistic for cash flow and financial performance improvements.
Read more →IRIXIridex to Report Third Quarter 2025 Financial Results on November 11, 2025
Iridex Corporation, a leader in laser-based medical systems, is set to release its financial results for the third quarter of 2025 on November 11, 2025. Following the announcement, a conference call will be hosted by the management team for investors. This event is viewed as an opportunity for the company to provide insights into its business performance and operations in the ophthalmology market, particularly in treatments for glaucoma and retinal diseases.
Read more →IRIXIridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Corporation has received formal notification from Nasdaq confirming its compliance with continued listing requirements. This follows a previous notification of non-compliance due to insufficient stockholders' equity. The company has now met the minimum requirement of $2.5 million, closing the matter. Iridex specializes in laser-based medical systems for ophthalmology.
Read more →IRIXIridex Reports Second Quarter 2025 Financial Results
Iridex Corporation reported its financial results for the second quarter of 2025, showing a total revenue of $13.6 million, which is a 7% year-over-year increase. The company achieved a 14% sequential growth compared to the first quarter of 2025 and reported its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, net loss improved slightly to $1.0 million, and the Cyclo G6 product family experienced flat revenue year-over-year. Looking ahead, Iridex aims to achieve cash flow breakeven and continue its focus on improving financial discipline and operational efficiency.
Read more →IRIXIridex to Report Second Quarter 2025 Financial Results on August 12, 2025
Iridex Corporation plans to announce its financial results for the second quarter of 2025 on August 12, 2025. The announcement will be followed by a conference call at 2:00 p.m. PT. The company specializes in laser-based medical systems for treating glaucoma and retinal diseases, with a strong international presence.
Read more →IRIXIridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
Iridex Corporation has announced the enrollment of the first patient in the DAME Trial, an independent study evaluating the addition of MicroPulse treatments to anti-VEGF therapy for diabetic macular edema (DME). Led by Professor Noemi Lois, the trial aims to assess the efficacy, safety, and cost-effectiveness of this combined treatment approach. The study will involve 264 participants across the UK and seeks to establish a new treatment pathway for DME management.
Read more →IRIXIridex Reports First Quarter 2025 Financial Results
Iridex Corporation reported its financial results for Q1 2025, highlighting a total revenue of $11.9 million, a slight increase from the previous year. The Cyclo G6 product family saw an 8% revenue increase due to higher probe and system sales. Operating expenses decreased significantly by 32%, contributing to an adjusted EBITDA of $0.4 million, marking a turnaround from prior losses. However, the company reported a net loss of $1.7 million, primarily due to a decrease in retina product sales.
Read more →IRIXIridex to Report First Quarter 2025 Financial Results on May 13, 2025
Iridex Corporation has announced its plans to release its financial results for the first quarter of 2025 on May 13, 2025. Following the announcement, the management team will hold a conference call to discuss the results and provide a business update. This event is of interest to investors and stakeholders, especially given Iridex's prominent role in developing laser-based medical systems for eye conditions.
Read more →IRIXIridex Announces Preliminary Operational and Financial Results for the First Quarter 2025
Iridex Corporation has announced preliminary operational and financial results for Q1 2025, highlighting a stabilization of business and improved financial condition following a strategic investment. The company reported revenue increases over the past two quarters while significantly reducing operating expenses. An investor call is scheduled for April 16, 2025, to discuss the strategic vision of Iridex and Novel.
Read more →IRIXIridex to Host Strategic Vision Call on April 16, 2025
Iridex Corporation will host a strategic vision call on April 16, 2025, to discuss its future direction following a recent investment from Novel. The call will feature the management team and will be accessible to investors via phone and webcast. Iridex is known for its innovative laser-based medical systems for treating eye conditions.
Read more →IRIXIridex Reports Fourth Quarter and Full Year 2024 Financial Results
Iridex Corporation reported its financial results for the fourth quarter and full year of 2024, highlighting a successful cost reduction program and a positive adjusted EBITDA in the fourth quarter. The company's revenue increased slightly compared to the prior year quarter, but full-year revenue experienced a decrease due to lower sales in its retina product line. Notably, Iridex reduced its net loss and improved its balance sheet with a strategic investment. Looking ahead, the company aims to maintain this operational discipline to enhance cash flow and financial stability.
Read more →IRIX▼ -20.8%on this news
Iridex Announces Strategic Investment in the Company
Iridex Corporation announced a $10 million strategic investment from Novel Inspiration International Co., Ltd., aimed at supporting growth initiatives. This investment includes the sale of new Series B Preferred Stock and convertible notes, with an option for additional funding. CEO Patrick Mercer expressed optimism for future collaborations that leverage their expertise in laser-based treatments, especially following the recent reimbursement landscape changes. Additionally, the appointment of Romeo Dizon as CFO signals a shift in leadership during this strategic transition.
Read more →IRIX▲ +16.5%on this newsshared move
Iridex Comments on Recent Stock Price Volatility
Iridex Corporation has addressed recent volatility in its stock price, stating that there are no known material developments affecting its operating or financial condition. The company confirmed that its recent performance remains in line with previous updates given in January. A conference call is scheduled for March 27, 2025, to discuss the final fourth quarter and full year 2024 financial results, providing investors with more insights into the company's status.
Read more →IRIX▼ -21.1%on this newsshared move
Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025
Iridex Corporation (NASDAQ: IRIX) announced plans to report its financial results for the fourth quarter and full year 2024 on March 27, 2025. A conference call will follow their announcement, showcasing management's willingness to update investors. The company is known for its innovative laser-based medical systems for treating eye conditions, with a broad market presence in over 100 countries.
Read more →IRIXIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2024
Iridex Corporation, a leader in laser-based medical systems, announced its preliminary financial results for Q4 and the full year 2024. The company expects Q4 revenues to slightly outperform the previous year, signaling stable sales of its Cyclo G6 products despite facing operational challenges. However, the overall revenue for the year is projected to decline compared to 2023. The company is committed to improving profitability and enhancing operational efficiency amid strategic reviews and cost restructuring.
Read more →IRIXIridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
Iridex Corporation announced the publication of a landmark five-year study demonstrating the long-term effectiveness and safety of MicroPulse Transscleral Laser Therapy (TLT) for glaucoma management. Conducted by researchers at the University Eye Clinic Maastricht, the study found significant reductions in intraocular pressure and a low complication rate among patients. Only 38% of treated eyes required retreatment during the follow-up period, indicating the sustainability of treatment outcomes. This peer-reviewed study establishes MicroPulse TLT as a viable, less invasive alternative to traditional surgeries for glaucoma patients.
Read more →IRIXIridex Comments on Changing Glaucoma Reimbursement Landscape
Iridex Corporation has announced that the Local Coverage Determination (LCD) L37531 regarding Micro-Invasive Glaucoma Surgery (MIGS) will be effective from November 17, 2024. The company believes the new reimbursement limitations will enhance interest in its laser-based glaucoma treatments, particularly since their Cyclo G6 products are unaffected by these restrictions. Industry experts have highlighted the clinical importance of Iridex's therapies, suggesting that the LCD may encourage physicians to consider non-MIGS procedures more seriously as they treat glaucoma patients.
Read more →IRIXIridex Reports Third Quarter 2024 Financial Results
Iridex Corporation (Nasdaq: IRIX) reported its financial results for the third quarter of 2024, highlighting a total revenue of $11.6 million, which reflects an 8% sequential decline and a 10% year-over-year decrease. The company anticipates reaching EBITDA breakeven in the upcoming fourth quarter due to cost-reduction measures. Despite challenges in the retina product segment, the Cyclo G6 product family experienced a year-over-year revenue increase. Recent Medicare reimbursement updates may positively influence the adoption of Iridex's glaucoma treatments.
Read more →IRIX▼ -5%on this news
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
Iridex Corporation has announced that it will report its financial results for the third quarter of 2024 on November 12, 2024. The company, known for its laser-based medical systems, will also provide a business update following the results. A conference call for investors will be held to discuss these updates. Iridex continues to focus on delivering innovative treatments for eye conditions, including glaucoma and retinal diseases.
Read more →IRIXIridex Appoints Patrick Mercer as Chief Executive Officer
Iridex Corporation has announced the appointment of Patrick Mercer as its new Chief Executive Officer and President, effective October 1, 2024. Mercer previously served as the Chief Operating Officer, providing continuity in leadership during a period of strategic review for potential transactions. Meanwhile, Scott Shuda has been appointed as the Executive Chairman of the board. The change aims to accelerate progress towards unlocking the company's assets and enhancing its market presence in ophthalmic care.
Read more →IRIXIridex Reports Second Quarter 2024 Financial Results
Iridex Corporation reported its financial results for Q2 2024, revealing a total revenue of $12.6 million, which is a 7% increase from Q1 2024. Key product lines, including the Cyclo G6, saw notable growth, particularly in probe sales and sequential performance in its Retina segment. Nonetheless, the company reported a net loss of $2.7 million, down slightly from the prior year's loss, and experienced a decrease in cash reserves. The management highlighted ongoing strategic initiatives and the recent convertible note funding as efforts towards sustaining growth and shareholder value.
Read more →IRIX▼ -9.7%on this newsshared move
Iridex Announces Convertible Note Financing
Iridex Corporation has announced a private placement financing of a senior convertible promissory note, expected to yield approximately $3.5 million in net proceeds. The company may also issue an additional note for another $1.5 million, bringing total potential proceeds to around $5 million. This financing is part of Iridex's strategy to improve liquidity and support future growth, while implementing significant expense reductions. The Convertible Notes will allow for repayment flexibility and potential options for pre-payment, enhancing the company's balance sheet health.
Read more →IRIX▼ -9.7%on this newsshared move
MOUNTAIN
Iridex Corporation announced a private placement financing of a senior convertible promissory note with Lind Global Asset Management, intended to raise approximately $3.5 million. Additionally, a follow-on note could provide an extra $1.5 million, bringing total potential proceeds to about $5 million. The financing aims to enhance the company's liquidity and support its strategic growth processes. The notes have a 24-month term, convertible into common stock at an initial price of $2.44 per share.
Read more →IRIXIridex to Report Second Quarter 2024 Financial Results on August 8, 2024
Iridex Corporation (NASDAQ: IRIX) has announced that it will release its financial results for the second quarter of 2024 on August 8, 2024. A conference call will be hosted by the management team at 2:00 PM PT/5:00 PM ET on the same day, where investors can join either by phone or through a webcast. This update highlights the company's ongoing commitment to investor communication and transparency within the ophthalmology market, where it specializes in laser-based therapies for glaucoma and retinal diseases.
Read more →IRIXIridex Reports First Quarter 2024 Financial Results
Iridex Corporation reported its financial results for Q1 2024, revealing a total revenue of $11.8 million, down from $13.7 million in the same period last year. The company's Cyclo G6 product family and retina products also experienced revenue declines. Despite these challenges, management noted signs of recovery in the second quarter, with increased interest in new product offerings. Continuous strategic discussions regarding potential transactions are ongoing to enhance value for shareholders.
Read more →IRIXIridex to Report First Quarter 2024 Financial Results on May 14, 2024
Iridex Corporation, a leader in laser-based medical systems for ophthalmology, will report its financial results for the first quarter of 2024 on May 14, 2024. Following the release, management will host a conference call for investors at 2:00 p.m. PT. The company specializes in devices for the treatment of glaucoma and retinal diseases, utilizing proprietary technology in its operations.
Read more →IRIXIridex Reports Fourth Quarter and Full Year 2023 Financial Results
Iridex Corporation reported disappointing financial results for the fourth quarter and full year of 2023. Total revenue fell to $12.5 million in Q4, a decline from $15.2 million in Q4 2022, with significant drops in both Cyclo G6 product and retina product sales. The report cited various factors contributing to this decrease, including restrictive Medicare reimbursements and decreased international distributor orders. Looking forward, the company launched new products and reported signs of improved business flow in early 2024.
Read more →IRIXIridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
Iridex Corporation has announced the upcoming release of its financial results for the fourth quarter and full year 2023, scheduled for March 26, 2024. Additionally, the company will provide an update on its strategic review process. A conference call will take place at 2:00 p.m. PT to discuss these results and updates. Iridex, known for its laser-based medical systems for eye conditions, aims to keep investors informed on its progress and strategies.
Read more →IRIXIridex Corporation Receives European Patent on MicroPulse Technology
Iridex Corporation has received the European Patent EP 3009093 for its MicroPulse technology, designed to improve laser treatments in ophthalmology. This innovative technology facilitates controlled laser pulse delivery, reducing the risks associated with traditional methods. The patent strengthens Iridex's intellectual property position and underscores its commitment to advancing medical laser treatments. The unique characteristics of MicroPulse technology allow for safer and more effective procedures in managing eye diseases such as glaucoma and diabetic macular edema.
Read more →IRIXIridex Announces First Patient Enrollment in MicroPulse TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
Iridex Corporation has announced the first patient enrollment in a clinical study evaluating the treatment of glaucoma with MicroPulse Transscleral Laser Therapy (TLT), developed in collaboration with Imperial College Healthcare NHS Trust. This study, titled 'MicroPulse Transscleral Laser Therapy: A Prospective UK Study,' seeks to expand Iridex's global clinical portfolio over a three-year period. The partnership aims to advance glaucoma treatment by implementing a large-scale enrollment platform, while both organizations commit to adhering to ethical and regulatory standards throughout the study.
Read more →IRIXIridex Launches New Iridex 532 and Iridex 577 Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
Iridex Corporation has launched its new Iridex 532® and Iridex 577® lasers in the U.S. market, coinciding with its 35th anniversary. These advanced lasers include features such as continuous-wave and MicroPulse® Technology, designed to improve treatment for retinal disorders and glaucoma. The new laser systems offer enhanced user experience and comprehensive treatment reports, receiving positive feedback from medical professionals for their design and functionality. The launch highlights Iridex's ongoing commitment to innovation in ocular treatment technologies.
Read more →IRIXIridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
Iridex Corporation announced that all five Medicare Administrative Contractors (MACs) have retired their local coverage determinations (LCDs) that would have restricted reimbursements for cyclophotocoagulation procedures. This decision maintains Medicare coverage for Iridex's glaucoma treatment options. The company collaborated with stakeholders to advocate for patient access, highlighting the significance of collective efforts in shaping healthcare policies. As a result, the effective date for the proposed restrictions has been removed, ensuring uninterrupted access to treatment for patients.
Read more →IRIX▲ +19%on this news
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
Iridex Corporation has successfully appealed for changes to the Medicare Local Coverage Determinations (LCDs) for Cyclophotocoagulation, allowing broader patient access. The five Medicare Administrative Contractors amended coverage criteria based on advocacy efforts that highlighted errors in the original listings. Iridex's president expressed satisfaction with the revisions but also indicated plans for further appeals to expand qualifying patient criteria. This achievement reflects a commitment to align coverage with established medical recommendations and advancing patient care.
Read more →IRIX▼ -7.3%on this news
Iridex Reports Third Quarter 2023 Financial Results and Business Update
Iridex Corporation reported its third quarter 2023 financial results, noting revenues of $12.9 million, which reflects a 12% decrease from the previous year. The company's retina product sales experienced a sequential increase, but overall, the company is grappling with new Medicare restrictions that may limit reimbursement for certain glaucoma procedures. These changes raise concerns about the impact on the company's glaucoma business, which constitutes a significant portion of its revenue. Iridex plans to appeal the coverage criteria set by Medicare Administrative Contractors to protect its market position.
Read more →IRIXIridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
Iridex Corporation announced its plans to host a third quarter financial results conference call on November 14, 2023, at 2:00 p.m. PT. Additionally, the company will participate in the Stifel Healthcare Conference on November 15, 2023, in New York City. Investors can access the live and recorded webcasts on Iridex's website. This engagement with investors underscores the company's commitment to transparency and communication while emphasizing its innovative ophthalmic products.
Read more →IRIX▼ -5.8%on this news
GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE In re IRIDEX CORP. ) C.A. No. 2023- ) [PROPOSED] ORDER GRANTING PETITION FOR RELIEF PURSUANT TO 8 DEL. C. 205 WHEREAS, on
The Delaware Court of Chancery has issued a ruling validating the Operative Charter of IRIDEX Corporation, originally filed in 1996. This decision comes after the company filed a Verified Petition for Relief, seeking validation due to potential authorization failures. The court's order grants good cause for the petition, ensuring that prior corporate actions taken by IRIDEX remain effective. Judge Nathan A. Cook presided over the case, affirming the importance of this ruling for the company's continued operations.
Read more →IRIXIridex to Report Third Quarter Financial Results on November 14, 2023
Iridex Corporation, a leading provider of ophthalmic laser-based medical products, has announced that it will release its third quarter financial results on November 14, 2023. The company's proprietary MicroPulse technology is noted for its efficacy in treating glaucoma and diabetic macular edema. Iridex markets its products both domestically and internationally across over 100 countries. The announcement could provide insights into the company’s financial health and business performance.
Read more →IRIXIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE In re IRIDEX CORP. ) C.A. No. 2023 __________ ) VERIFIED PETITION FOR RELIEF PURSUANT TO 8 DEL. C. 205 Petitioner IRIDEX Corporation ("IRIDEX" or the "Company"), by and t
IRIDEX Corporation has filed a petition in Delaware's Court of Chancery to validate its Amended and Restated Certificate of Incorporation from 1996. The company is addressing a challenge from a putative stockholder alleging potential defects in the adoption of its charter. This legal uncertainty has raised concerns over prior corporate actions and could hinder IRIDEX's capacity to raise capital and engage in future transactions. The company seeks a retroactive declaration that its charter is valid.
Read more →IRIX▲ +6.6%on this news· ran to +30% by day 3
Iridex Announces Strategic Review to Unlock Shareholder Value
Iridex Corporation (Nasdaq: IRIX) has initiated a strategic review process with the aim of exploring alternatives to unlock shareholder value. The company has enlisted Piper Sandler as a financial advisor for this process. Iridex is recognized for its leadership in laser-based medical systems for ophthalmology, particularly in glaucoma and retinal diseases. While the company has experienced growth and innovation in its product lines, there is no guarantee that the strategic review will lead to favorable transactions.
Read more →IRIXIridex Reports Second Quarter 2023 Financial Results
Iridex Corporation reported its financial results for the second quarter of 2023, revealing a total revenue decrease of 7% year-over-year to $12.9 million. While the Cyclo G6 product family showed growth, particularly in probes sold, overall revenue from the retina product line declined by 9%. The company also reported a widening net loss of $2.8 million compared to the previous year. However, management expressed confidence in upcoming initiatives and stabilization of capital demand in the latter half of the year.
Read more →IRIXIridex to Report Second Quarter Financial Results on August 10, 2023
Iridex Corporation has announced it will report its financial results for the second quarter of 2023 on August 10, 2023. The release will occur after the market closes, followed by a conference call at 2:00 p.m. PT. The company specializes in laser-based medical devices for treating glaucoma and retinal diseases, showcasing its commitment to advancing ophthalmic health. Interested investors can participate in the call via a live and recorded webcast.
Read more →IRIXIridex Reports First Quarter 2023 Financial Results
Iridex Corporation reported its first quarter financial results for 2023, showing a modest increase in total revenue to $13.7 million, primarily driven by growth in the Cyclo G6 product family. The company saw an increase in Cyclo G6 sales, alongside receiving FDA clearance for a new laser platform. However, net losses were recorded at $2.1 million, which was an improvement over the previous year's loss. Additionally, despite some declines in unit sales and reduced gross margins, Iridex maintains a positive outlook for the remainder of 2023.
Read more →IRIXIridex to Report First Quarter Financial Results on May 11, 2023
Iridex Corporation will report its financial results for the first quarter of 2023 on May 11, 2023, after market close. The management team will conduct a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Iridex is recognized for its innovative laser-based medical products aimed at treating glaucoma, diabetic macular edema, and other retinal diseases, with products available globally through various distribution channels.
Read more →IRIXIridex Reports Fourth Quarter and Full Year 2022 Financial Results Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth
Iridex Corporation reported its financial results for Q4 and the full year of 2022, showcasing a 6% increase in annual total revenue to $57 million. The company achieved record sales in its Cyclo G6 glaucoma probes, contributing to a 9% increase in this sector. However, the revenue from Retina products saw an 11% decline, and the overall net loss for 2022 rose to $7.5 million. Looking ahead, Iridex projected a 3% to 6% revenue growth for 2023, driven by anticipated sales of Cyclo G6 probes and recent FDA clearances for new products.
Read more →IRIXIridex to Present at the 35th Annual Roth Conference
Iridex Corporation (Nasdaq: IRIX) will present at the 35th Annual Roth Conference on March 14, 2023, at 11:00 am PT. The event will allow interested parties to access a live and archived webcast on the company's website. Iridex specializes in laser-based medical products for treating glaucoma and retinal diseases, highlighting their commitment to innovation in ophthalmology.
Read more →IRIXIridex Introduces New Research and Showcases Five Events at the AGS Meeting
Iridex Corporation (NASDAQ: IRIX) showcased five events at the 2023 American Glaucoma Society meeting in Austin, Texas, aimed at highlighting advancements in MicroPulse Transscleral Laser Therapy (TLT). The publication of Part 2 of evidence-based guidelines for MicroPulse TLT was announced, confirming safety and effectiveness through a consensus by ten glaucoma experts. Attendees will have opportunities to see live presentations, demos of new software, and celebrate Dr. Douglas Gaasterland’s contributions to ophthalmology. This event marks a significant push forward in optimizing surgical techniques and enhancing treatment outcomes for glaucoma.
Read more →IRIXIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
Iridex Corporation announced it will release its financial results for the fourth quarter and full year 2022 on March 9, 2023. Following the release, the management team will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET for investors to discuss the results. Iridex is known for its innovative ophthalmic laser-based medical products aimed at treating glaucoma and retinal diseases, underscoring its leadership in the medical technology industry.
Read more →IRIX▲ +6.1%on this news
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022 Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth
Iridex Corporation reported preliminary operational and financial results for Q4 and the full year of 2022, highlighting a record 16,400 Cyclo G6 probes sold in the fourth quarter and an overall revenue growth of 6% for the year. Despite steady revenue, the company faced a decrease in sales of Cyclo G6 Glaucoma Laser Systems compared to the previous year. The operational results are based on management's initial analysis and are subject to further review and potential adjustments. Iridex aims to drive growth in 2023 through the adoption of new platforms and increased utilization of Cyclo G6 products.
Read more →IRIXIridex to Participate in Fireside Chat with Stifel Equity Research
MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat wit
Read more →IRIXIridex Announces Record Third Quarter 2022 Financial Results Company Announces FDA Clearance of new Iridex Pascal Scanning Laser Platform
Iridex Announces Record Third Quarter 2022 Financial Results Company Announces FDA Clearance of new Iridex Pascal Scanning Laser Platform MOUNTAIN VIEW, Calif., November 10, 2022 -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical produ
Read more →IRIXIridex to Report Third Quarter 2022 Financial Results on November 10, 2022
MOUNTAIN VIEW, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the thir
Read more →IRIXIridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022
MicroPulse® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to manage, preserve, and prolong vision for glaucoma patients. Sweep Management
Read more →IRIXIridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
MOUNTAIN VIEW, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the company will present at the upcoming Inaugural Gilm
Read more →IRIXIridex Announces Second Quarter 2022 Financial Results
Iridex Announces Second Quarter 2022 Financial Results MOUNTAIN VIEW, Calif., August 15, 2022 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights -Total revenue of $13.8 million, an inc
Read more →IRIXIridex to Report Second Quarter 2022 Financial Results on August 15, 2022
MOUNTAIN VIEW, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the seco
Read more →IRIXIridex Obtains Regulatory Clearance for Cyclo G6 Glaucoma Platform in China
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and
Read more →IRIXIridex Announces First Quarter 2022 Financial Results Achieved Record First Quarter Revenue
Iridex Announces First Quarter 2022 Financial Results Achieved Record First Quarter Revenue MOUNTAIN VIEW, Calif., May 12, 2022 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022. First Quarter 2022 Highlights "Reco
Read more →IRIXIridex to Report First Quarter 2022 Financial Results on May 12, 2022
MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fir
Read more →IRIXIridex Announces the Appointment of Beverly Huss to its Board of Directors
Iridex Announces the Appointment of Beverly Huss to its Board of Directors MOUNTAIN VIEW, Calif., March 21, 2022 -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today annou
Read more →IRIXIridex Announces Fourth Quarter and Full Year 2021 Financial Results Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth
Iridex Announces Fourth Quarter and Full Year 2021 Financial Results Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth MOUNTAIN VIEW, Calif., March 10, 2022 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fo
Read more →IRIXIridex to Present at the 34th Annual Roth Conference
MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34th
Read more →IRIXIridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the four
Read more →IRIXIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth MOUNTAIN VIEW, Calif., January 11, 2022 -- Iridex Corporation (Nasdaq: IRIX) today
Read more →IRIX▼ -10.7%on this news
Iridex to Present at the 2021 Stifel Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 2021 S
Read more →IRIXIridex Announces Third Quarter 2021 Financial Results Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance
Iridex Announces Third Quarter 2021 Financial Results Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance MOUNTAIN VIEW, Calif., November 11, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 2
Read more →IRIXIridex to Report Third Quarter 2021 Financial Results on November 11, 2021
MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the thir
Read more →IRIXIridex to Present at the Lytham Partners Fall 2021 Investor Conference
MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming Lytha
Read more →IRIXIridex Announces Second Quarter 2021 Financial Results Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance
Iridex Announces Second Quarter 2021 Financial Results Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance MOUNTAIN VIEW, Calif., August 12, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for
Read more →IRIXIridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference
MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C. W
Read more →IRIXIridex to Report Second Quarter 2021 Financial Results on August 12, 2021
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the seco
Read more →IRIXIridex Announces First Quarter 2021 Financial Results
Iridex Announces First Quarter 2021 Financial Results MOUNTAIN VIEW, Calif., May 11, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021. First Quarter Highlights "We enjoyed a strong start to 2021 and our positi
Read more →IRIXIridex to Report First Quarter 2021 Financial Results on May 11, 2021
MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fir
Read more →IRIXIridex Announces Fourth Quarter and Full Year 2020 Financial Results
Iridex Announces Fourth Quarter and Full Year 2020 Financial Results MOUNTAIN VIEW, Calif., March 22, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021. Fourth Quarter Highlights "Despite the challe
Read more →IRIXIridex Completes Transaction with Topcon Corporation
MOUNTAIN VIEW, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transac
Read more →IRIXIridex Completes Transaction with Topcon Corporation Mountain View, CA
Iridex Completes Transaction with Topcon Corporation Mountain View, CA - March 10, 2021 - Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed
Read more →IRIXIridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fou
Read more →IRIXIridex Announces Strategic Collaboration with Topcon Corporation
Transaction provides $19.5 million cash to Iridex, as two leaders join forces in glaucoma and retinal disease treatment Iridex to host a conference call presentation on March 2, 2021 at 2:00 p.m. PT/5:00 p.m. ET MOUNTAIN VIEW, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Iridex C
Read more →IRIXIridex Announces Strategic Collaboration with Topcon Corporation Transaction provides $19.5 million cash to Iridex, as two leaders join forces in glaucoma and retinal disease treatment Iridex to hos
Iridex Announces Strategic Collaboration with Topcon Corporation Mountain View, CA - March 2, 2021 - Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it ha
Read more →IRIXIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020
IRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020 MOUNTAIN VIEW, Calif., January 11, 2021 -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and fu
Read more →IRIXIRIDEX Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelines
Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma MOUNTAIN VIEW, Calif., Dec. 22, 2020 (
Read more →IRIXIRIDEX Announces Third Quarter 2020 Financial Results
IRIDEX Announces Third Quarter 2020 Financial Results MOUNTAIN VIEW, Calif., November 9, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020. Third Quarter Summary "We are encouraged by continued recovery fr
Read more →IRIXIRIDEX to Present at the 2020 Stifel Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference. David I. Bruce, IRIDEX’s President and Chief Executive Officer, is scheduled to prese
Read more →IRIXIRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020
MOUNTAIN VIEW, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020. The Company’s management team will host a co
Read more →IRIXIRIDEX Announces Second Quarter 2020 Financial Results
IRIDEX Announces Second Quarter 2020 Financial Results MOUNTAIN VIEW, Calif., August 6, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020. Second Quarter Summary Commenting on the quarter, David I. Bruce, Pres
Read more →IRIXIRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020
MOUNTAIN VIEW, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of trading on Thursday, August 6, 2020. The Company’s management team will host a
Read more →IRIXIRIDEX Announces First Quarter 2020 Financial Results
IRIDEX Announces First Quarter 2020 Financial Results MOUNTAIN VIEW, Calif., May 11, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 28, 2020. Commenting on the recently completed quarter and the business environment
Read more →IRIXIRIDEX to Report First Quarter 2020 Financial Results on May 11, 2020
MOUNTAIN VIEW, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020. The Company’s management team will host a corre
Read more →IRIXIRIDEX Announces the Appointment of Doris Engibous to its Board of Directors Mountain View, Calif.
IRIDEX Announces the Appointment of Doris Engibous to its Board of Directors Mountain View, Calif. April 21, 2020 -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today anno
Read more →IRIXIRIDEX ANNOUNCES RETIREMENT OF VP FINANCE Names Prior CFO/COO as Interim CFO Mountain View, Calif.
IRIDEX ANNOUNCES RETIREMENT OF VP FINANCE Names Prior CFO/COO as Interim CFO Mountain View, Calif. March 30, 2020 -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced
Read more →IRIXIRIDEX ANNOUNCES RETIREMENT OF VP FINANCE
MOUNTAIN VIEW, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Romeo Dizon has retired from his position as Vice
Read more →IRIXIRIDEX Announces Fourth Quarter and Full Year 2019 Financial Results
IRIDEX Announces Fourth Quarter and Full Year 2019 Financial Results MOUNTAIN VIEW, Calif., March 12, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28, 2019. Fourth Quarter Highlights "IRIDEX has made significa
Read more →IRIXIRIDEX to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
MOUNTAIN VIEW, Calif., Feb. 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year of 2019 after the close of trading on Thursday, March 12, 2020. The Company’s management tea
Read more →IRIXIRIDEX Launches Revised MicroPulse P3 Device for Glaucoma
MOUNTAIN VIEW, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today the introduction of the second generation of the MicroP
Read more →IRIXIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2019
IRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2019 MOUNTAIN VIEW, Calif., January 13, 2020 -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year en
Read more →IRIXIRIDEX Announces 2019 Third Quarter Financial Results
MOUNTAIN VIEW, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28, 2019. Third Quarter Highlights Total revenue of $10.7 million Cyclo G6® product family revenue of $3.0 million,
Read more →IRIXIRIDEX to Present at the 2019 Stifel Healthcare Conference
MOUNTAIN VIEW, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Healthcare Conference in New York City. David I. Bruce, IRIDEX’s President and Chief Executive Officer, is scheduled
Read more →IRIXIRIDEX Announces Appointment of Robert Gunst as Chairman of the Board of Directors and Departure of Lead Independent Director, Ruediger Naumann-Etienne Mountain View, Calif.
IRIDEX Announces Appointment of Robert Gunst as Chairman of the Board of Directors and Departure of Lead Independent Director, Ruediger Naumann-Etienne Mountain View, Calif., October 28, 2019- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Robert Gunst as C
Read more →IRIXIRIDEX to Report Third Quarter 2019 Financial Results on November 7, 2019
MOUNTAIN VIEW, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2019 after the close of trading on Thursday, November 7, 2019. The Company’s management team will host a
Read more →IRIXIRIDEX Announces 2019 Second Quarter Financial Results
IRIDEX Announces 2019 Second Quarter Financial Results MOUNTAIN VIEW, Calif., August 6, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 29, 2019. Second Quarter Highlights "I am pleased to join the IRIDEX team at thi
Read more →IRIXIRIDEX to Report Second Quarter 2019 Financial Results on August 6, 2019
MOUNTAIN VIEW, Calif., July 23, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2019 after the close of trading on Tuesday, August 6, 2019. The Company’s management team will host a c
Read more →IRIXIRIDEX Announces Leadership Transition; David Bruce Appointed President and CEO Mountain View, Calif.
IRIDEX Announces Leadership Transition; David Bruce Appointed President and CEO Mountain View, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal
Read more →IRIXIRIDEX Announces 2019 First Quarter Financial Results
IRIDEX Announces 2019 First Quarter Financial Results MOUNTAIN VIEW, Calif., May 2, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2019. First Quarter Highlights "Our first quarter results were solid, representi
Read more →IRIXIRIDEX’s MicroPulse Laser Technology Featured in Several Glaucoma and Retina Research Presentations at Major Ophthalmic Industry Conferences
MOUNTAIN VIEW, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® technology played a pivo
Read more →IRIXScott Shuda Appointed to IRIDEX Board of Directors Mountain View, Calif.
Scott Shuda Appointed to IRIDEX Board of Directors Mountain View, Calif. April 29, 2019 -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Scott Shuda has
Read more →IRIXIRIDEX to Report First Quarter 2019 Financial Results on May 2, 2019
MOUNTAIN VIEW, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2019 after the close of trading on Thursday, May 2, 2019. The Company’s management team will host a cor
Read more →IRIXKen Ludlum Appointed to IRIDEX Board of Directors Mountain View, Calif.
Ken Ludlum Appointed to IRIDEX Board of Directors Mountain View, Calif. April 2, 2019 -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Ken Ludlum has be
Read more →IRIXIRIDEX to Present at the Spring Investor Summit
MOUNTAIN VIEW, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming Spring Investor Summit in New York, NY. Chairman and CEO William Moore is scheduled to present on Monday, April 1, 2019 at 3:0
Read more →IRIXIRIDEX to Present at the 31st Annual Roth Conference
MOUNTAIN VIEW, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming 31st Annual Roth Conference in Orange County, CA. Management is scheduled to present on Tuesday, March 19, 2019 at 9:00 AM PT.
Read more →IRIXIRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results
MOUNTAIN VIEW, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018. Fourth Quarter Highlights Cyclo G6® product revenue increased approximately 16% year-over-year
Read more →IRIXIRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) December 29, December 30 , 2018 2017 Assets Current assets: Cash and cash equivalents $ 21,194 $ 21,707 Accounts receivable, net 9,083
IRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results MOUNTAIN VIEW, Calif., March 5, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018. Fourth Quarter Highlights "I am pleased with
Read more →IRIXIRIDEX to Report Fourth Quarter and 2018 Financial Results on March 5, 2019
MOUNTAIN VIEW, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5, 2019. The Company’s management team wil
Read more →IRIXIRIDEX Announces Resolution of its Dispute with Quantel Medical Mountain View, Calif.
IRIDEX Announces Resolution of its Dispute with Quantel Medical Mountain View, Calif., February 12, 2019- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, "Quant
Read more →IRIXIRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year Mountain View, Calif.
IRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year Mountain View, Calif., January 8, 2019- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended
Read more →IRIXIRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance Mountain View, Calif.
IRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance Mountain View, Calif., December 4, 2018- IRIDEX Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive rol
Read more →IRIXIRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance
MOUNTAIN VIEW, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018. Third Quarter Highlights Cyclo G6™ product revenue increased approximately 23% year-over-y
Read more →IRIXIRIDEX to Participate in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in upcoming investor conferences. IRIDEX’s management is scheduled to present at the Stephens NY Investment Conference on Wednesday, Novemb
Read more →IRIXIRIDEX to Report Third Quarter 2018 Financial Results on November 1, 2018
MOUNTAIN VIEW, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter 2018 after the close of trading on Thursday, November 1, 2018. The Company’s management team will host a co
Read more →IRIXIRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors Mountain View, Calif.
IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors Mountain View, Calif., October 15, 2018- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Dr. Robert Grove to the Company's Board of Directors effective October 15, 2018. Concurr
Read more →IRIXIRIDEX Announces Pricing of Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 14, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatenin
Read more →IRIXIRIDEX Announces Proposed Public Offering of Common Stock
MOUNTAIN VIEW, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatenin
Read more →IRIXIRIDEX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Mountain View, California
IRIDEX ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Mountain View, California, September 13, 2018 IRIDEX Corporation (NASDAQ:IRIX) ( IRIDEX or the Company ), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products
Read more →IRIXIRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market
MOUNTAIN VIEW, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of its updated TruFocus LIO Premiere™ laser accessory following U.S. Food and Drug Administration (FDA) 510(k) review and clearance. The TruFocus LIO Prem
Read more →IRIXIRIDEX Cyclo G6™ Laser System for Glaucoma Treatment Used in Majority of Top U.S. Ophthalmology Hospitals
MOUNTAIN VIEW, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophtha
Read more →IRIXIRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance
MOUNTAIN VIEW, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018. Second Quarter Highlights Cyclo G6™ product revenue increased approximately 58% year-over-year
Read more →IRIXJune 30, December 30, , 2018 2017 Assets Current assets: Cash and cash equivalents $ 16,045 $ 21,707 Accounts receivable, net 7,142 7,863 Inventories 9,093 9,381 Prepaid expenses and other current assets 653 500 Total cu
IRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance MOUNTAIN VIEW, Calif., August 2, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018. Second Quarter Highlights "I'
Read more →IRIXIRIDEX to Report Second Quarter 2018 Financial Results on August 2, 2018
MOUNTAIN VIEW, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2, 2018. The Company’s management team will host a cor
Read more →IRIXIRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped
MOUNTAIN VIEW, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser System, which utilizes the Company’s proprietary MicroPulse® technology for the trea
Read more →IRIXIRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in Korea
MOUNTAIN VIEW, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS). Currently available in more than 50 countries, the CYCLO G6 tre
Read more →IRIXIRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) March 31, December 30, , 2018 2017 Assets Current assets: Cash and cash equivalents $ 18,522 $ 21,707 Accounts receivable, net 6,400 7
IRIDEX Announces 2018 First Quarter Financial Results MOUNTAIN VIEW, Calif., May 3, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 31, 2018. First Quarter Highlights "We're off to a solid start in 2018 and are makin
Read more →IRIXIRIDEX Announces 2018 First Quarter Financial Results
MOUNTAIN VIEW, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the first quarter ended March 31, 2018. First Quarter Highlights Cyclo G6™ product revenue increased approximately 50% year-over-year Shipped a record
Read more →IRIXIRIDEX to Report First Quarter 2018 Financial Results on May 3, 2018
MOUNTAIN VIEW, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the first quarter 2018 after the close of trading on Thursday, May 3, 2018. The Company’s management team will host a corresp
Read more →IRIXIRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors Mountain View, Calif.
IRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors Mountain View, Calif., April 16, 2018- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Maria Sainz and David Bruce to the Company's Board of Directors effective as of April
Read more →IRIXIridex Receives CE Mark for Transilluminated Probe
MOUNTAIN VIEW, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) is pleased to announce the availability of the G-Probe Illuminate™ device in Europe. The probe, now with CE mark, offers combined transillumination and laser fiber for targeted transscleral
Read more →IRIXIRIDEX Announces 2017 Fourth Quarter and Full Year Financial Results
MOUNTAIN VIEW, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and full year ended December 30, 2017. Fourth Quarter Highlights Fourth quarter 2017 revenue for Cyclo G6™ glaucoma laser platfor
Read more →IRIXIRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) December 30, December 31, , 2017 2016 Assets Current assets: Cash and cash equivalents $ 21,707 $ 23,747 Accounts receivable, net 7,86
IRIDEX Announces 2017 Fourth Quarter and Full Year Financial Results Shipped Record Cyclo G6 Laser Systems and G6 Probes MOUNTAIN VIEW, Calif., March 8, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and full year ended Decembe
Read more →IRIXIRIDEX to Present at the 30th Annual Roth Conference
MOUNTAIN VIEW, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in the upcoming 30th Annual Roth Conference in Orange County, CA. IRIDEX’s management is scheduled to present on Tuesday, March 13, 2018 at
Read more →IRIXIRIDEX Issues Voluntary Recall of TruFocus LIO Premiere Laser Indirect Ophthalmoscope Updates Preliminary Financial Results for 2017 Fourth Quarter and Full Year FOR IMMEDIATE RELEASE
IRIDEX Issues Voluntary Recall of TruFocus LIO Premiere Laser Indirect Ophthalmoscope Updates Preliminary Financial Results for 2017 Fourth Quarter and Full Year FOR IMMEDIATE RELEASE: February 23, 2018 1212 Terra Bella Avenue Mountain View, CA 94043 On February 23, 2018, IR
Read more →IRIXIRIDEX to Report Fourth Quarter and 2017 Financial Results on March 8, 2018
MOUNTAIN VIEW, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team wil
Read more →IRIXIRIDEX Announces Infringement Lawsuit Against Quantel
IRIDEX Announces Infringement Lawsuit Against Quantel MOUNTAIN VIEW, Calif., January 9, 2018 -- IRIDEX Corporation (NASDAQ:IRIX) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. District Court for the Nor
Read more →IRIXwhich was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact Lynn Pieper Lewis or Lei
IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year MOUNTAIN VIEW, Calif., January 8, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ende
Read more →IRIXIRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year
MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017. Total revenue for the fourth quarter of 2017 expected to be $11.0
Read more →IRIXForward Looking Statements Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make fo
Investor Presentation November 2017 Exhibit 99.1 Forward Looking Statements Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-look
Read more →IRIXIRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) September 30
IRIDEX Announces 2017 Third Quarter Financial Results MOUNTAIN VIEW, Calif., November 2, 2017 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 30, 2017. Third Quarter Highlights "Sales of our G6 systems
Read more →IRIXIRIDEX Announces 2017 Third Quarter Financial Results
MOUNTAIN VIEW, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the third quarter and nine months ended September 30, 2017. Third Quarter Highlights Record third quarter revenue of $10.9 million, an 11% year-over-ye
Read more →IRIXIRIDEX to Present at Upcoming Investor Conferences
MOUNTAIN VIEW, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in two upcoming investor conferences. November 9, 2017 at 1:30pm ET, IRIDEX’s management is scheduled to present at the Canaccord Genuity Me
Read more →IRIXIRIDEX to Report Third Quarter 2017 Financial Results on November 2, 2017
MOUNTAIN VIEW, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the third quarter 2017 after the close of trading on Thursday, November 2, 2017. The Company’s management team will host a cor
Read more →IRIXIRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands and unaudited) July 1, December 31, , 2017 2016 Assets Current assets: Cash and cash equivalents $ 24,594 $ 23,747 Accounts receivable, net 7,049 10,
IRIDEX Announces 2017 Second Quarter, Six-Month Financial Results Updates Guidance for Full Year 2017 MOUNTAIN VIEW, Calif., August 3, 2017 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 1, 2017. Second Qu
Read more →IRIXnumber of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31 , 2016, and Quarterly Reports on Form 10-Q for subsequent fi
IRIDEX ANNOUNCES APPOINTMENT OF ANN RHOADS TO ITS BOARD OF DIRECTORS MOUNTAIN VIEW, Calif., July 18, 2017 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Ann Rhoads to the Company's Board of Directors, Audit Committee, and Compensation Committee, effectiv
Read more →IRIXIRIDEX Announces First Quarter 2017 Financial Results Updates Guidance for Full Year 2017
IRIDEX Announces First Quarter 2017 Financial Results Updates Guidance for Full Year 2017 MOUNTAIN VIEW, Calif., May 3, 2017 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the three months ended April 1, 2017. Recent Financial Results and Highlights
Read more →IRIXIRIDEX Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial Outlook Cyclo G6 Glaucoma Laser Platform Fourth Quarter Revenue Up 67% Year-over-Year Record Revenue of $12.5 Million in th
IRIDEX Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial Outlook Cyclo G6 Glaucoma Laser Platform Fourth Quarter Revenue Up 67% Year-over-Year Record Revenue of $12.5 Million in the Fourth Quarter of 2016 MOUNTAIN VIEW, Calif., March 8,
Read more →IRIXIRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year Mountain View, CA.
IRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year Mountain View, CA. - January 9, 2017 - IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $12.4 to $12.5 million and $46.0 to $46.1 million for the fourth qu
Read more →IRIXIRIDEX Corporation Prices Public Offering of Common Stock
IRIDEX Corporation Prices Public Offering of Common Stock MOUNTAIN VIEW, Calif., Dec. 9, 2016 /PRNewswire/ IRIDEX Corporation (NASDAQ: IRIX) today announced the pricing of its underwritten public offering of an aggregate of 1.15 million shares of common stock at a price of $14.
Read more →IRIXirix-ex991_6.pptx.htm IRIDEX Corporation Corporate Presentation November 2016 NASDAQ: IRIX IRIDEX Corporation Corporate Presentation November 2016 NASDAQ: IRIX Safe Harbor Participation in this presentation requires that
IRIDEX Corporation Corporate Presentation November 2016 NASDAQ: IRIX IRIDEX Corporation Corporate Presentation November 2016 NASDAQ: IRIX Safe Harbor Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Ac
Read more →IRIXIRIDEX Reports 2016 Third Quarter, Nine-Month Results Cyclo G6 Glaucoma Laser Platform Third Quarter Revenues Up 442 Percent Year-over-Year Mountain View, CA.
IRIDEX Reports 2016 Third Quarter, Nine-Month Results Cyclo G6 Glaucoma Laser Platform Third Quarter Revenues Up 442 Percent Year-over-Year Mountain View, CA. - November 3, 2016 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine
Read more →IRIXIRIDEX Announces Preliminary Revenues for 2016 Third Quarter Mountain View, CA.
IRIDEX Announces Preliminary Revenues for 2016 Third Quarter Mountain View, CA. October 11, 2016 IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $9.6 to $9.7 million for the third quarter ended October 1, 2016 compared to prior revenue gui
Read more →IRIXIRIDEX Reports 2016 Second Quarter, Six-Month Results Total Revenues Up 32 Percent Year-over-Year for Second Quarter; Cyclo G6 Glaucoma Laser System Revenues Up 66 Percent Sequentially Mountain View
IRIDEX Reports 2016 Second Quarter, Six-Month Results Total Revenues Up 32 Percent Year-over-Year for Second Quarter; Cyclo G6 Glaucoma Laser System Revenues Up 66 Percent Sequentially Mountain View, CA. - August 4, 2016 - IRIDEX Corporation (Nasdaq: IRIX) today reported finan
Read more →IRIXIRIDEX ANNOUNCES ATABAK MOKARI WILL BE CHIEF FINANCIAL OFFICER AND VP CORPORATE DEVELOPMENT Mountain View, CA
IRIDEX ANNOUNCES ATABAK MOKARI WILL BE CHIEF FINANCIAL OFFICER AND VP CORPORATE DEVELOPMENT Mountain View, CA, July 11, 2016 IRIDEX Corporation (Nasdaq: IRIX) today announced that Atabak Mokari, 39, will join the Company as Chief Financial Officer and Vice President of Corporat
Read more →IRIXSafe Harbor Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-looking s
IRIDEX Corporation Singular Research Conference - San Francisco, CA NASDAQ: IRIX June 9, 2016 Exhibit 99.1 Safe Harbor Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of
Read more →IRIXIRIDEX Reports 2016 First Quarter Results Record First Quarter Revenues Revenues Up 11 Percent Versus First Quarter of 2015 Mountain View, CA.
IRIDEX Reports 2016 First Quarter Results Record First Quarter Revenues Revenues Up 11 Percent Versus First Quarter of 2015 Mountain View, CA. - May 5, 2016 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2016. Preside
Read more →IRIXIRIDEX Reports 2015 Fourth Quarter, Full Year Results Revenues Up 3 Percent versus Fourth Quarter of 2014 Revenues Up 23 Percent Sequentially for Fourth Quarter Mountain View, CA.
IRIDEX Reports 2015 Fourth Quarter, Full Year Results Revenues Up 3 Percent versus Fourth Quarter of 2014 Revenues Up 23 Percent Sequentially for Fourth Quarter Mountain View, CA. - March 3, 2016 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the four
Read more →IRIXIRIDEX Announces Preliminary Unaudited Revenues for 2015 Fourth Quarter and Full Year Year-End Strength in Both Glaucoma and Retinal Laser Systems and Procedures
IRIDEX Announces Preliminary Unaudited Revenues for 2015 Fourth Quarter and Full Year Year-End Strength in Both Glaucoma and Retinal Laser Systems and MOUNTAIN VIEW, Calif., Jan. 11, 2016 IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $1
Read more →IRIXIRIDEX Reports 2015 Third Quarter, Nine-Month Results Mountain View, CA.
IRIDEX Reports 2015 Third Quarter, Nine-Month Results Mountain View, CA. - November 5, 2015 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended October 3, 2015. President and CEO Will Moore said, "The third quarter pe
Read more →IRIXIRIDEX Reports 2015 Second Quarter, Six-Month Results Mountain View, CA.
IRIDEX Reports 2015 Second Quarter, Six-Month Results Mountain View, CA. - August 6, 2015 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 4, 2015. President and CEO Will Moore said, "Demand for our products r
Read more →IRIXIRIDEX Chief Financial Officer Resigns to Accept Another Opportunity
IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity MOUNTAIN VIEW, Calif., August 4, 2015 IRIDEX Corporation (Nasdaq:IRIX) today announced that James H. Mackaness, who had served as chief financial officer since 2008 and as chief operating officer since 2012, h
Read more →IRIXIRIDEX Announces Preliminary Revenues for 2015 Second Quarter
IRIDEX Announces Preliminary Revenues for 2015 Second Quarter MOUNTAIN VIEW, Calif., July 16, 2015 -- IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $9.0 to $9.1 million and $19.8 to $19.9 million for the second quarter and first six months
Read more →IRIXIRIDEX Reports 2015 First Quarter Results Record Q1 Revenues Mountain View, CA.
IRIDEX Reports 2015 First Quarter Results Mountain View, CA. - May 7, 2015 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 4, 2015. President and CEO Will Moore said, "Our business continued its strong momentum into the fir
Read more →IRIXIRIDEX Reports 2014 Fourth Quarter, Year-End Results Record Revenues for the Quarter and the Year Mountain View, CA.
IRIDEX Reports 2014 Fourth Quarter, Year-End Results Record Revenues for the Quarter and the Year Mountain View, CA. - March 5, 2015 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 3, 2015. President and CEO Wi
Read more →IRIXIRIDEX Announces Preliminary Unaudited Revenues for 2014 Fourth Quarter and Full Year; 2015 Revenue Outlook Mountain View, Calif.
IRIDEX Announces Preliminary Unaudited Revenues for 2014 Fourth Quarter and Full Year; 2015 Revenue Outlook Mountain View, Calif., January 12, 2015 IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $11.5 to $11.7 million and $42.5 to $42.7 m
Read more →IRIXMedical Laser Veteran George R. Marcellino, Ph.D. Appointed to IRIDEX Board of Directors Mountain View, Calif.
Medical Laser Veteran George R. Marcellino, Ph.D. Appointed to IRIDEX Board of Directors Mountain View, Calif., December 31, 2014 IRIDEX Corporation (NASDAQ:IRIX) announced today that it has appointed ophthalmology and medical laser executive George R. Marcellino, Ph.D., to its
Read more →IRIXIRIDEX Reports 2014 Third Quarter, Nine-Month Results Mountain View, CA.
IRIDEX Reports 2014 Third Quarter, Nine-Month Results Mountain View, CA. - October 30, 2014 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 27, 2014. President and CEO Will Moore said, "We posted a solid
Read more →IRIXIRIDEX Reports 2014 Second Quarter, Six-Month Results Revenue Up 15% Year over Year for Both Periods Board of Directors Establishes New Share Repurchase Program Mountain View, CA.
IRIDEX Reports 2014 Second Quarter, Six-Month Results Revenue Up 15% Year over Year for Both Periods Board of Directors Establishes New Share Repurchase Program Mountain View, CA. - July 31, 2014 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the seco
Read more →IRIXIRIDEX Reports 2014 First Quarter Results Revenue Up 16% to $10.3 Million Year over Year Mountain View, CA.
IRIDEX Reports 2014 First Quarter Results Revenue Up 16% to $10.3 Million Year over Year Mountain View, CA. - May 1, 2014 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 29, 2014. President and CEO Will Moore said, "We had
Read more →IRIXIRIDEX Reports 2013 Fourth Quarter Results Record Revenue of $10.6 Million in Quarter Mountain View, Calif.
IRIDEX Reports 2013 Fourth Quarter Results Record Revenue of $10.6 Million in Quarter Mountain View, Calif. - February 27, 2014 - IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28, 2013. President and CEO Will Moore sai
Read more →IRIXIRIDEX Announces Preliminary Unaudited Revenues For 2013 Fourth Quarter and Year End
IRIDEX Announces Preliminary Unaudited Revenues For 2013 Fourth Quarter and Year End MOUNTAIN VIEW, Calif., January 28, 2014 -- IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $10.6 million and $38.3 million for the fourth quarter and full
Read more →IRIXIRIDEX Reports 2013 Third Quarter Results RECORD REVENUE OF $9.5 MILLION IN QUARTER Mountain View, Calif.
IRIDEX Reports 2013 Third Quarter Results RECORD REVENUE OF $9.5 MILLION IN QUARTER Mountain View, Calif. October 31, 2013 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28, 2013. Revenues were $9.5 million in the th
Read more →IRIXIRIDEX Reports 2013 Second Quarter Results; $9.2 Million Record Q2 Revenue Mountain View, Calif.
IRIDEX Reports 2013 Second Quarter Results; $9.2 Million Record Q2 Revenue Mountain View, Calif. August 1, 2013 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 29, 2013. Revenues were $9.2 million in the second quarter of
Read more →IRIXIRIDEX Reports 2013 First Quarter Results Profits Increase as Commercial Progress and Operational Streamlining Continue
IRIDEX Reports 2013 First Quarter Results Profits Increase as Commercial Progress and Operational Streamlining Continue MOUNTAIN VIEW, Calif., May 2, 2013 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2013. CEO Willia
Read more →IRIXIRIDEX Reports Record 2012 Fourth Quarter Results Board Approves New $3.0 Million Stock Repurchase Program Mountain View, Calif.
IRIDEX Reports Record 2012 Fourth Quarter Results Board Approves New $3.0 Million Stock Repurchase Program Mountain View, Calif. February 28, 2013 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 29, 2012. CEO William M.
Read more →IRIXIRIDEX Reports 2012 Third Quarter Results Mountain View, Calif.
IRIDEX Reports 2012 Third Quarter Results Mountain View, Calif. November 1, 2012 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 29, 2012. Interim CEO William M. Moore said, IRIDEX implemented a number of important strat
Read more →IRIXIRIDEX Appoints Chairman William M. Moore as Interim President & CEO CFO James Mackaness to Assume COO Responsibilities Mountain View, Calif.
IRIDEX Appoints Chairman William M. Moore as Interim President & CEO CFO James Mackaness to Assume COO Responsibilities Mountain View, Calif. August 28, 2012 IRIDEX Corporation (Nasdaq: IRIX) today announced that its Board of Directors has named medical device industry veteran
Read more →IRIXIRIDEX Reports 2012 Second Quarter Results Mountain View, Calif.
IRIDEX Reports 2012 Second Quarter Results Mountain View, Calif. August 2, 2012 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 30, 2012. Due to the sale of the Company s aesthetics laser business in February 2012, the Compan
Read more →IRIXIRIDEX Reports 2012 First Quarter Results Mountain View, Calif.
IRIDEX Reports 2012 First Quarter Results Mountain View, Calif. May 3, 2012 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 31, 2012. Due to the sale of the Company s aesthetics laser business in February 2012, the Company s
Read more →IRIXIRIDEX Reports 2011 Fourth Quarter and Year-End Results Mountain View, Calif.
IRIDEX Reports 2011 Fourth Quarter and Mountain View, Calif. - March 1, 2012 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 31, 2011. Due to the sale of the Company s aesthetics laser business in February 2012, the Compa
Read more →IRIXIRIDEX Corporation Executive Management Bonus Plan Summary EFFECTIVE DATE January 1st, 2012 PURPOSE The purpose of the Plan is to provide an incentive for the achievement of Goals that support IRIDEX Strategic Plan. TERM
IRIDEX Corporation Executive Management Bonus Plan Summary EFFECTIVE DATE January 1st, 2012 PURPOSE The purpose of the Plan is to provide an incentive for the achievement of Goals that support IRIDEX Strategic Plan. TERMS AND DEFINITIONS PLAN NAME The Executive Management Bonus P
Read more →IRIXCutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit Purchase positions Cutera as a leader in the vascular aesthetic market; and refocuses IRIDEX on core ophthalmology opportunit
Cutera and IRIDEX Announce Acquisition of IRIDEX Aesthetic Business Unit Purchase positions Cutera as a leader in the vascular aesthetic market; and refocuses IRIDEX on core ophthalmology opportunity Brisbane, Calif. and Mountain View, Calif. January 3, 2012 Cutera, Inc. (NASD
Read more →IRIXIRIDEX Reports 2011 Third Quarter and Nine-Month Results Mountain View, Calif.
IRIDEX Reports 2011 Third Quarter and Nine-Month Results Mountain View, Calif. November 3, 2011 IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 1, 2011. Third quarter results exceeded guidance for all categories: revenue,
Read more →IRIXEXECUTION COPY IRIDEX CORPORATION EMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) is entered into as of
EMPLOYMENT AGREEMENT This Employment Agreement (the Agreement ) is entered into as of August 16, 2011 by and between Iridex Corporation (the Company ), and Dr. Dominik Beck 1. Duties and Scope of Employment. (a) Positions and Duties. Executive will serve as President and Chief
Read more →IRIXIRIDEX Reports Growing Revenue and Profits in 2011 Second Quarter Mountain View, Calif.
IRIDEX Reports Growing Revenue and Profits in Mountain View, Calif. August 4, 2011 IRIDEX Corporation (Nasdaq: IRIX) today reported improved financial results for the second quarter ended July 2, 2011. Second quarter sales were within guidance, gross margin was below guidance
Read more →IRIXIRIDEX Reports Growing Revenue and Profits in 2011 First Quarter Announces Stock Repurchase Program Mountain View, Calif.
IRIDEX Reports Growing Revenue and Profits in Announces Stock Repurchase Program Mountain View, Calif. May 5, 2011 IRIDEX Corporation (Nasdaq: IRIX) today reported that growing demand for new products and consumables drove sales and improved financial results for the first qua
Read more →IRIXIRIDEX Corporation 2011 Senior Staff Bonus Plan Summary Objective: To provide cash incentive bonus payouts to eligible employees based upon Company and individual performance in exceeding Revenue performance and Operatin
2011 Senior Staff Bonus Plan Summary To provide cash incentive bonus payouts to eligible employees based upon Company and individual performance in exceeding Revenue performance and Operating Income performance to Plan. Company Director-level, VP and Corporate Officers, in goo
Read more →IRIXIRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter Quarterly Profit increases 62% as Sales and Gross Margins Strengthen Record Operating Income and Strong Cash Generation for the Year M
IRIDEX Reports Strong Growth and Profits in Quarterly Profit increases 62% as Sales and Gross Margins Strengthen Record Operating Income and Strong Cash Generation for the Year Mountain View, Calif. - March 3, 2011 IRIDEX Corporation (Nasdaq: IRIX) today reported that growing
Read more →IRIXJim Mackaness Chief Financial Officer (650) 940-4700
FOR IMMEDIATE RELEASE Contact: Jim Mackaness Chief Financial Officer (650) 940-4700 Mountain View, California IRIDEX Reports Improved Third Quarter 2010 Financial Results IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended O
Read more →IRIXJim Mackaness Chief Financial Officer 650 940-4700
FOR IMMEDIATE RELEASE Contact: Jim Mackaness Chief Financial Officer 650 940-4700 Mountain View, California IRIDEX Reports Second Quarter 2010 Financial Results IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 3, 20
Read more →IRIXIRIDEX Corporation 2010 Employee Incentive Program Summary Objective: To provide cash incentive payouts to all eligible employees based upon Company profitability and individual performance. Eligibility: Executive office
2010 Employee Incentive Program Summary provide cash incentive payouts to all eligible employees based upon Company profitability and individual performance. Executive officers and all other employees in good standing, except for commissioned sales personnel, are eligible to p
Read more →IRIXIRIDEX Corporation 2009 Employee Incentive Program Summary Objective: To provide cash incentive payouts to all eligible employees based upon Company and individual performance. Eligibility: Executive officers and employe
2009 Employee Incentive Program Summary To provide cash incentive payouts to all eligible employees based upon Company and individual performance. Executive officers and employees who are employed by the Company and in good standing when the payout is paid are eligible. Commi
Read more →IRIXTheodore A. Boutacoff Chief Executive Officer (650) 940-4700
FOR IMMEDIATE RELEASE Contact: Theodore A. Boutacoff Chief Executive Officer (650) 940-4700 Mountain View, California IRIDEX ANNOUNCES JAMES MACKANESS WILL BE CHIEF IRIDEX Corporation (Nasdaq: IRIX) today announced that James H. Mackaness, 44, will join the Company
Read more →IRIXTheodore A. Boutacoff President and CEO 650-940-4700
For Immediate Release Contact: Theodore A. Boutacoff President and CEO 650-940-4700 IRIDEX REPORTS THIRD QUARTER FINANCIAL RESULTS MOUNTAIN VIEW, CA, November 19, 2007 IRIDEX Corporation (NASDAQ: IRIX) today reported financial results for the quarter ended September
Read more →IRIXTheodore A. Boutacoff Appointed President CEO of
Theodore A. Boutacoff Appointed President CEO of IRIDEX MOUNTAIN VIEW, Calif., Oct. 17, 2007 IRIDEX Corporation (Nasdaq: IRIX) announced today that Barry Caldwell has resigned as the Company s President and Chief Executive Officer, and as a member of the Board of Directors, ef
Read more →IRIXLarry Tannenbaum Chief Business Officer (650) 940-4700
FOR IMMEDIATE RELEASE Contact: Larry Tannenbaum Chief Business Officer (650) 940-4700 Mountain View, California James B. Hawkins Appointed to IRIDEX Board of Directors Natus Medical CEO Brings More Than 20 Years of Public Company Experience IRIDEX Corporation (NASDA
Read more →IRIXLarry Tannenbaum Chief Business Officer 650-940-4700
Mountain View, California WILLIAM MOORE APPOINTED TO IRIDEX BOARD OF DIRECTORS Moore is Director at BlueLine Partners, Recent Equity Investors in IRIDEX IRIDEX Corporation (Nasdaq: IRIX) announced today the appointment of William M. Moore to its Board of Directors. Mr. Moore,
Read more →IRIXIRIDEX Announces Closing of $5.0 Million Private Placement
IRIDEX Announces Closing of $5.0 Million Private Placement MOUNTAIN VIEW, Calif., Sept. 5, 2007 IRIDEX Corporation (Nasdaq: IRIX) today announced that it has raised $5.0 million in gross proceeds via a private placement conducted with BlueLine Partners which closed on August 3
Read more →Competitive Position
How IRIX ranks across every disease it competes inCompetitive Position is a premium feature
See how IRIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial